Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands
Apretude 600 mg prolonged-release suspension for injection.
| Pharmaceutical Form |
|---|
|
Prolonged-release suspension for injection. White to light pink suspension. |
Each vial contains 600 mg cabotegravir in 3 mL.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cabotegravir |
Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. |
| List of Excipients |
|---|
|
Mannitol (E421) |
Brown 3 mL type I glass vial, with bromobutyl rubber stopper and a grey aluminium overseal with an orange plastic flip-cap.
Pack sizes of 1 vial or 25 vials. Not all pack sizes may be marketed.
ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands
EU/1/23/1760/002
EU/1/23/1760/003
| Drug | Countries | |
|---|---|---|
| APRETUDE | Estonia, France, Croatia, Ireland, Italy, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
